Pharmacological control of the PPARγ pathway and its regulators by both TZDs and statins, respectively used for treating diabetes and dyslipidemia, illustrates the molecular interplay among pathways involved in the pathogenesis and therapy of these two disease states. This evidence concerns the gene PPARG and metabolic syndrome.